Helena Earl

Apr 15, 2024 | thelancet.com | Charlotte Coles |Helena Earl |Benjamin O. Anderson |Carlos H. Barrios

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Apr 15, 2024 | thelancet.com | Charlotte Coles |Helena Earl |Benjamin O. Anderson |Carlos H. Barrios

Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes Despite tremendous advances in breast cancer research and treatment over the past three decades—leading to a reduction in breast cancer mortality of over 40% in some high-income countries—gross inequities remain, with many groups being systematically left behind,...

Apr 3, 2024 | thelancet.com | Helena Earl

Among HER2-positive EBC patients, a PET-based, pCR-adapted strategy was associated with an excellent 3-year iDFS. This strategy identified about a third of patients who had HER2-positive EBC who could safely omit chemotherapy.